Single-versus multiple-tablet HIV regimens: Adherence and hospitalization risk

American Journal of Managed Care

Volumn 22, Issue 4, 2016, Pages 242-248

  Sutton, S Scott ^a,b   Hardin, James W ^a,b   Bramley, Thomas J ^c   D'Souza, Anna O ^c   Bennett, Charles L ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WJB Dorn VA Medical Center   (United States)

^c XCENDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALCOHOL ABUSE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG DOSE REGIMEN; ELECTRONIC HEALTH RECORD; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL HEALTH; MULTIPLE TABLET REGIMEN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE TABLET REGIMEN; TREATMENT OUTCOME; VIRUS LOAD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; COMPARATIVE STUDY; DRUG EFFECTS; FACTUAL DATABASE; GOVERNMENT; MEDICAID; MIDDLE AGED; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VIRAL LOAD;

EID: 84966586679     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hall HI, Song R, Rhodes P, et al; HIV Incidence Surveillance Group. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-529. doi: 10.1001/jama.300.5.520.
2. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007-2010 [HIV Surveillance Supplemental Report]. CDC website. http://www.cdc.gov/hiv/pdf/statistics-hssr-vol-17-no-4.pdf. Published December 2012. Accessed December 20, 2013.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents; Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo website. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 20, 2014.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
5. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417-1423.
6. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357-366.
7. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24(18): 2835-2840. doi: 10.1097/QAD.0b013e328340a209
8. Fielden SJ, Rusch ML, Yip B, et al. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART. J Int Assoc Physicians AIDS Care (Chic). 2008;7(5):238-244. doi: 10.1177/1545109708323132.
9. Kitahata MM, Reed SD, Dillingham PW, et al. Pharmacy-based assessment of adherence to HAART predicts virological and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004;15(12):803-810.
10. 9 cells/L. Ann Intern Med. 2003;139(10):810-816.
11. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181-1183.
12. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40(1):158-163.
13. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr. 2005;40(3):294-300.
14. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6(3):185-190.
15. Juday T, Gupta S, Grimm K, Wagner S, Kim E. Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials. 2011;12(2):71-78. doi: 10.1310/hct1202-71.
16. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE. 2012;7(2):e31591. doi: 10.1371/journal.pone.0031591.
17. Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US Medicaid population with HIV. BMJ Open. 2013;3(8):e003028.
18. Thompson MA, Aberg JA, Cahn P, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-333. doi: 10.1001/jama.2010.1004.
19. HIV treatment: FDA-approved anti-HIV medications. AIDSinfo website. http://www.aidsinfo.nih.gov/contentfiles/ApprovedMedstoTreatHIV-FS-en.pdf. Updated March 15, 2016. Accessed March 21, 2016.
20. Moore KH, Shaw S, Laurent AL, et al. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol. 1999;39(6):593-605.
21. Crémieux AC, Katlama C, Gillotin C, Demarles D, Yuen GJ, Raffi F; AZI10002 Study Group. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. Pharmacotherapy. 2001;21(4):424-430.
22. Legorreta A, Yu A, Chernicoff H, Gilmore A, Jordan J, Rosenzweig JC. Adherence to combined lamivudine + zidovudine versus individual components: a community-based retrospective Medicaid claims analysis. AIDS Care. 2005;17(8):938-948.
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9 CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
24. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48(4):484-488. doi: 10.1086/596482.
25. van Galen KA, Nellen JF, Nieuwkerk PT. The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis. AIDS Res Treat. 2014;2014:967073. doi: 10.1155/2014/967073.
26. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297-1307. doi: 10.1093/cid/ciu046.
27. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011;52(4):493-506. doi: 10.1093/cid/ciq167.
28. Daar ES, Tierney C, Fischl MA, et al; AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445-456. doi: 10.7326/0003-4819-154-7-201104050-00316.
29. Riddler SA, Haubrich R, DiRienzo AG, et al; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-2106. doi: 10.1056/NEJMoa074609.